NeurAxis (NRXS)
Prescription ear-worn stimulation for functional abdominal pain and a rectal-expulsion diagnostic device.
NRXS Stock Dips Post Q2 Earnings Despite Revenue Surge, Gross Margin Up
NeurAxis delivers record second-quarter 2026 revenues as stronger IB-Stim demand, higher pricing and an improved reimbursement mix lift gross margin.
NeurAxis, Inc. (NRXS) Q2 2026 Earnings Call Transcript
NeurAxis, Inc. (NRXS) Q2 2026 Earnings Call Transcript
NeurAxis Expands Payer Coverage with New Policies
CARMEL, Ind., Aug. 04, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced additional medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), representing over 500,000 covered lives. This coverage will expand incremental access to IB-Stim treatment for beneficiaries in the Mid-Atlantic region.
NeurAxis to Host Second Quarter 2026 Results and Business Update Call on Tuesday, August 11, 2026
CARMEL, Ind., July 28, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its second quarter period ended June 30, 2026, on Tuesday, August 11, 2026, before market open. The Company has scheduled a conference call for the same day, Tuesday, August 11, 2026, at 9:00 am ET to review the results.
NeurAxis, Inc. (NRXS) Q1 2026 Earnings Call Transcript
NeurAxis, Inc. (NRXS) Q1 2026 Earnings Call Transcript
NeurAxis Reports Record First Quarter 2026 Financial Results Driven by 80% Year Over Year Revenue Growth
CARMEL, Ind., May 12, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the first quarter period ended March 31, 2026.
NeurAxis to Host First Quarter 2026 Results and Business Update Call on Tuesday, May 12, 2026
CARMEL, Ind., May 05, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its first quarter 2026, for the period ended March 31, 2026, on Tuesday, May 12, 2026, before market open. The Company has scheduled a conference call for the same day, Tuesday, May 12, 2026, at 9:00 am ET to review the results.
NeurAxis Expands Payer Coverage with Four New Medical Policies
CARMEL, Ind., April 22, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced four additional health insurers with medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), representing approximately 1.25 million covered lives. These medical policies expand incremental access to IB-Stim treatment for beneficiaries in West Virginia, New Hampshire, South Carolina, Virginia, and Florida.
NeurAxis, Inc. Announces Preferred Stock Dividend
CARMEL, Ind., April 10, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced that on April 10, 2026, its Board of Directors declared a dividend on its Series B Preferred Stock.
NeurAxis Stock Gains Post Q4 Earnings on Strong Revenue Growth
NRXS witnesses strong revenue growth and expanding coverage in fourth-quarter 2025, but rising costs and commercialization investments weigh on profitability.
NeurAxis, Inc. (NRXS) Q4 2025 Earnings Call Transcript
NeurAxis, Inc. (NRXS) Q4 2025 Earnings Call Transcript
NeurAxis Reports Strong Fourth Quarter and Full Year 2025 Financial Results
CARMEL, Ind., March 19, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the fourth quarter period and full year ended December 31, 2025.
NeurAxis (NASDAQ:NRXS) Trading Down 5.7% – Here’s What Happened
NeurAxis, Inc. (NASDAQ: NRXS - Get Free Report) fell 5.7% during trading on Thursday. The company traded as low as $4.54 and last traded at $4.63. 136,167 shares changed hands during mid-day trading, an increase of 4% from the average session volume of 130,490 shares. The stock had previously closed at $4.91. Analyst Upgrades and
The Zacks Analyst Blog Meta, Bank of America, The Procter & Gamble, Espey and NeurAxis
Meta Platforms leads today???s Zacks Research Daily as AI-driven engagement and ad demand fuel growth, even as heavy AI investments raise monetization concerns.
NeurAxis (NASDAQ:NRXS) Stock Price Up 9.6% – Here’s Why
NeurAxis, Inc. (NASDAQ: NRXS - Get Free Report) shares rose 9.6% during mid-day trading on Wednesday. The company traded as high as $3.89 and last traded at $3.8150. Approximately 98,253 shares were traded during trading, a decline of 84% from the average daily volume of 598,177 shares. The stock had previously closed at $3.48. Analysts
NRXS Stock Declines Post Q3 Earnings Despite Continued Revenue Growth
NeurAxis posts its fifth straight quarter of double-digit expansion, but rising costs and margin pressure weigh on third-quarter 2025 results.
NeurAxis, Inc. (NRXS) Q3 2025 Earnings Call Transcript
NeurAxis, Inc. ( NRXS ) Q3 2025 Earnings Call November 11, 2025 9:00 AM EST Company Participants Brian Carrico - President, CEO & Director Timothy Henrichs - Chief Financial Officer Conference Call Participants Ben Shamsian Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the NeurAxis Reports Third Quarter 2025 Financial Results Conference Call.
NeurAxis Reports Strong Third Quarter 2025 Financial Results Driven by a 22% Growth in Revenues
Conference call will be held today, Tuesday, November 11 at 9:00 am ET Conference call will be held today, Tuesday, November 11 at 9:00 am ET
NeurAxis Stock Down Following Q2 Earnings Despite Revenue Growth
NRXS reports strong second-quarter 2025 revenue growth and lower losses, but gross margin compression remains a key concern.
NeurAxis, Inc. (NRXS) Q2 2025 Earnings Call Transcript
NeurAxis, Inc. (NYSE:NRXS ) Q2 2025 Earnings Conference Call August 12, 2025 9:00 AM ET Company Participants Brian Carrico - President, CEO & Director Timothy Robert Henrichs - Chief Financial Officer Conference Call Participants Ben Shamsian - Unidentified Company Chase Richard Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Lindsay Leeds - Unidentified Company Operator Good day, everyone, and welcome to the NeurAxis Report Second Quarter 2025 Financial Results. [Operator Instructions] Please note that this conference is being recorded.